Guardant360 CDx

FDA Premarket Approval P200010 S005

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

DeviceGuardant360 CDx
Generic NameNext Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System
ApplicantGuardant Health, Inc.505 Penobscot Driveredwood City, CA 94063 PMA NumberP200010 Supplement NumberS005 Date Received12/17/2021 Decision Date03/16/2022 Product Code PQP  Advisory Committee Pathology Supplement Typereal-time Process Supplement Reason Change Design/components/specifications/material Expedited Review Granted? No
Date Received2021-12-17
Decision Date2022-03-16
PMAP200010
SupplementS005
Product CodePQP 
Advisory CommitteePathology
Supplement TypeReal-time Process
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination ProductNo
Applicant AddressGuardant Health, Inc.
505 Penobscot Drive
redwood City, CA 94063 PMA NumberP200010 Supplement NumberS005 Date Received12/17/2021 Decision Date03/16/2022 Product Code PQP  Advisory Committee Pathology Supplement Typereal-time Process Supplement Reason Change Design/components/specifications/material Expedited Review Granted? No Combination ProductNo Approval Order Statement  
Approval To Use Reagent Lots Interchangeably For Guardant360 CDx Sample Preparation Kit Boxes And A Minor Software Update To Accommodate The Reagent Interchangeability Update.

Supplemental Filings

Supplement NumberDateSupplement Type
P200010Original Filing
S011 2022-07-01 30-day Notice
S010
S009
S008
S007 2022-02-02 30-day Notice
S006
S005 2021-12-17 Real-time Process
S004
S003
S002 2020-12-18 Panel Track
S001 2020-11-20 Panel Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.